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OBJECTIVE—The islet in type 2 diabetes is characterized by
-cell apoptosis, -cell endoplasmic reticulum stress, and islet
amyloid deposits derived from islet amyloid polypeptide (IAPP).
Toxic oligomers of IAPP form intracellularly in -cells in humans
with type 2 diabetes, suggesting impaired clearance of misfolded
proteins. In this study, we investigated whether human-IAPP
(h-IAPP) disrupts the endoplasmic reticulum–associated degra-
dation/ubiquitin/proteasome system.
RESEARCH DESIGN AND METHODS—We used pancreatic
tissue from humans with and without type 2 diabetes, isolated
islets from h-IAPP transgenic rats, isolated human islets, and INS
832/13 cells transduced with adenoviruses expressing either
h-IAPP or a comparable expression of rodent-IAPP. Immunoﬂu-
orescence and Western blotting were used to detect polyubiquiti-
nated proteins and ubiquitin carboxyl-terminal hydrolase L1
(UCH-L1) protein levels. Proteasome activity was measured in
isolated rat and human islets. UCH-L1 was knocked down by
small-interfering RNA in INS 832/13 cells and apoptosis was
evaluated.
RESULTS—We report accumulation of polyubiquinated pro-
teins and UCH-L1 deﬁciency in -cells of humans with type 2
diabetes. These ﬁndings were reproduced by expression of
oligomeric h-IAPP but not soluble rat-IAPP. Downregulation of
UCH-L1 expression and activity to reproduce that caused by
h-IAPP in -cells induced endoplasmic reticulum stress leading
to apoptosis.
CONCLUSIONS—Our results indicate that defective protein
degradation in -cells in type 2 diabetes can, at least in part, be
attributed to misfolded h-IAPP leading to UCH-L1 deﬁciency,
which in turn further compromises -cell viability. Diabetes 60:
227–238, 2011
T
ype 2 diabetes is characterized by a progressive
decline in -cell function in the face of insulin
resistance. Although the mechanisms underlying
-cell dysfunction are unknown, it is likely re-
lated to the presence of -cell endoplasmic reticulum (ER)
stress (1,2), increased -cell apoptosis (3,4), and de-
creased -cell mass (3,5). The islet in type 2 diabetes is
also characterized by amyloid deposits derived from islet
amyloid polypeptide (IAPP) (3). Insulin resistance, the
most important risk factor for development of type 2
diabetes, induces increased -cell expression of insulin
but to an even greater extent IAPP (6,7).
IAPP is a 37–amino acid peptide that is coexpressed and
cosecreted with insulin (8). This peptide has the propen-
sity to form amyloid ﬁbrils in species at risk of spontane-
ously developing diabetes (e.g., nonhuman primates and
cats). In contrast, in rodents, IAPP is not amyloidogenic
because of proline residue substitutions, and rodents do
not spontaneously develop type 2 diabetes with the islet
morphology present in humans (9). However, increased
expression of human-IAPP (h-IAPP) in rodents may lead to
type 2 diabetes with islet pathology comparable to that in
humans (10–14). Intracellular IAPP toxic oligomers and
ER stress have been reported in -cells of both humans
with type 2 diabetes and rodents with high expression of
h-IAPP (1,15,16).
The ER is responsible for synthesis, folding, and matu-
ration of proteins. It is endowed with a quality-control
system that facilitates the recognition of misfolded pro-
teins and targets them for degradation by the ubiquitin/
proteasome system (17). Efﬁcient removal of misfolded
proteins by the endoplasmic reticulum–associated degra-
dation (ERAD) is essential to protect cells from ER stress.
This is accomplished by several distinct steps. First, if a
protein fails quality control, it is removed from the ER by
retrograde translocation. Second, multiple ubiquitin mole-
cules are covalently attached to the targeted protein.
Third, the polyubiquinated protein is relocated to the 26S
proteasome. Fourth, the ubiquitin chains are removed
from the misfolded protein by a deubiquitinating enzyme,
and thus it is ﬁnally rendered available for degradation by
the passage through the 26S proteasome (18).
We recently reported that accumulation of polyubiquiti-
nated proteins occurs in pancreatic islets of h-IAPP trans-
genic mice but not in mice with comparable transgenic
expression of rodent-IAPP (r-IAPP) (16). This implies that
increased expression of h-IAPP may interfere with the
ERAD/ubiquitin/proteasome system, and thus contribute
to -cell ER stress. -Cells in type 2 diabetes share many
characteristics of neurons in neurodegenerative diseases,
such as Alzheimer’s and Parkinson’s diseases, also char-
acterized by protein misfolding, formation of toxic oli-
gomers of locally expressed amyloidogenic proteins, and
proteotoxicity prompting ER stress (9,19). These observa-
tions imply that the mechanisms that defend against
accumulation of misfolded proteins may be disrupted in
-cells in type 2 diabetes as previously documented in
neurodegenerative diseases (19–23). Of interest, impair-
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shown to contribute to neurotoxicity in some neurodegen-
erative diseases (20–23). In particular, deﬁciency in ubiq-
uitin carboxyl-terminal hydrolase L1 (UCH-L1) has been
observed in the brains of individuals with Alzheimer’s and
Parkinson’s diseases (24). UCH-L1, a member of the deu-
biquinating enzyme family, is abundantly expressed in
-cells (25) and neurons (26). UCH-L1 is required to
hydrolyze ubiquitin chains leading to both the release of
protein targeted for degradation from the ubiquitin chain
so that it can gain access to the proteasome and the
generation of free monomeric ubiquitin that is then avail-
able for further cycles of the ubiquitin system. Thus,
UCH-L1 deﬁciency impairs ubiquitin-dependent protein
degradation and results in accumulation of highly ubiqui-
tinated proteins (27–29).
Given the parallels between neurons in neurodegenera-
tive diseases and islets in type 2 diabetes, we hypothesized
that the ERAD/ubiquitin/proteasome system is compro-
mised in -cells in type 2 diabetes. Further, we hypothe-
sized that increased expression of amyloidogenic h-IAPP
would reproduce this dysfunction. Finally, we postulated
that the speciﬁc mechanism subserving the compromised
ERAD/ubiquitin/proteasome system in -cells in type 2
diabetes, and as a consequence of increased expression of
h-IAPP, is decreased availability of UCH-L1.
RESEARCH DESIGN AND METHODS
Cell culture. Rat insulinoma cell line INS 832/13 was provided by Dr. C.
Newgard (Durham, NC) (30). For the transduction experiments, cells were
plated on six-well plates at 10
6 cells/well, cultured for 24 h, and transduced
with r-IAPP or h-IAPP adenoviruses at 400 multiplicity of infection (MOI) for
48 h. At the end of the experiment, cells were lysed for 30 min at 4°C in a
solubilizing buffer (31).
Animal model: pancreas processing and islet isolation. The generation of
h-IAPP transgenic rats (HIP rats) has been described previously (10). Rats
were bred and housed at the animal housing facility of the University of
California Los Angeles (UCLA). The UCLA Institutional Animal Care and Use
Committee approved all surgical and experimental procedures. For immuno-
ﬂuorescence, wild-type and HIP rats (2 months old) were randomly assigned
to either a high-fat diet (HFD) (60% fat, 20% protein, and 20% carbohydrates;
Research Diets, New Brunswick, NJ) or a control regular diet (10% fat, 20%
protein, and 70% carbohydrates; Research Diets) and were fed ad libitum for
10 weeks (6) (supplementary Table 3 in the online appendix, available at
http://diabetes.diabetesjournals.org/cgi/content/full/db10-0522/DC1). Pancre-
ata were ﬁxed with 4% paraformaldehyde (Sigma), parafﬁn embedded, and cut
into 4-m sections. Islets were obtained from 4- to 6-month-old wild-type
(fasting blood glucose [FBG] 77  4 mg/dl) and prediabetic HIP rats (FBG
87  4 mg/dl) (as described in 16). Islets were lysed in lysis buffer (50 mmol/l
HEPES, 1% Nonidet P-40, 2 mmol/l Na3VO4, 100 mmol/l NaF, 10 mmol/l
PyrPO4, 4 mmol/l EDTA, 1 mmol/l PMSF, 1 g/ml leupeptin, and 1 g/ml
aprotinin), sonicated for 10 s, centrifuged, and stored at 20°C until use for
subsequent protein determination by bicinchoninic acid assay (Bio-Rad,
Hercules, CA) and Western blotting.
Human islets. Isolated human islets were obtained from the Islet Cell
Resource Consortium (http://icr.coh.org). The islet purity was 90–95%, as
assessed by dithizone staining. Islets used for transduction experiments were
obtained from nine heart-beating organ donors (ﬁve men and four women,
45  15 years of age, BMI 28  5 kg/m
2), and none had a previous history of
diabetes or metabolic disorders. Islet viability was 80–95%, as assessed by the
live/dead kit (Invitrogen). Islets were transduced with r-IAPP or h-IAPP
adenoviruses at 400 MOI for 72 h in RPMI-1640 medium containing 100
units/ml of penicillin, 100 g/ml of streptomycin, and 10% FBS (Invitrogen).
Islets used for analysis of ubiquitin or UCH-L1 expression were obtained from
four heart-beating organ donors with type 2 diabetes and three BMI-matched
nondiabetic control subjects (supplementary Table 1).
Human pancreatic tissue. Institutional review board approval was obtained
from the Mayo Clinic (no. 1516-03) and UCLA (no. 06-04-021-01). We obtained
human pancreatic tissue at autopsy from 6 lean nondiabetic subjects, 10 obese
subjects with type 2 diabetes, and 5 BMI-matched nondiabetic control
subjects (supplementary Table 2). Pancreas samples from subjects with type
2 diabetes were from individuals who had been treated with diet alone and/or
sulfonylurea treatment (FBG 172  26 mg/dl) or diet and insulin therapy (FBG
213  49 mg/dl). Pancreatic sections were stained with an anti-ubiquitin
antibody and stained in parallel for insulin to identify -cells. We obtained
nontumor-involved pancreatic tissue following surgical pancreatectomy for
pancreatic tumors from three nondiabetic humans and three obese humans
with type 2 diabetes (supplementary Table 4). Pancreas was processed as
previously described (1).
Western blotting. Proteins (25–50 g/lane) were separated on a 4–12%
Bis-Tris NuPAGE gel and blotted onto a nitrocellulose membrane (Whatman,
Germany). Membranes were probed overnight at 4°C with primary antibodies
against Poly (ADP-ribose) polymerase (PARP), phospho-eIF2- (Ser51), -ac-
tin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and ubiquitin from
Cell Signaling Technology (Beverly, MA); human ubiquitin from R&D Systems;
ubiquitin (clone FK2) from Biomol International (Plymouth Meeting, PA);
UCH-L1 from Chemicon International (Temecula, CA); -tubulin from Sigma;
C/EBP homologous protein (CHOP) from Santa Cruz Biotechnology (Santa
Cruz, CA); IAPP (25–37 aa) from Peninsula Laboratories (San Carlos, CA); and
insulin from Zymed Laboratories (San Francisco, CA). For detection of
apoptosis, membranes were probed with an antibody against the cleaved form
of caspase-3 (Cell Signaling Technology). We consider cleaved caspase-3 as a
reliable marker because a variety of alternative approaches have been
previously used in line with cleaved caspase-3 to support emergence of
apoptosis in the same models (1,6,32). Horseradish peroxidase–conjugated
secondary antibodies were from Zymed Laboratories. Proteins were visual-
ized by enhanced chemiluminescence (Millipore), and protein expression
levels were quantiﬁed using the Labworks software (UVP, Upland, CA).
Proteasome activity assay. Proteasome activity was assessed using the 20S
proteasome activity assay kit (Chemicon International) according to the
manufacturer’s protocol. Detection was made by spectroﬂuorometry (BioTek
Flx800), with excitation and emission wavelengths at 380 and 460 nm,
respectively. The optical density values were normalized to the protein
content.
UCH-L1 siRNA. UCH-L1 expression was silenced in INS 832/13 cells using
25-nucleotide stealth-prevalidated siRNA duplexes designed for rat UCH-L1
(Invitrogen). Cells were seeded in 12-well plates and grown overnight to reach
40–50% conﬂuency. The next day, lipofectAMINE2000-siRNA complexes were
prepared according to the manufacturer’s instructions. UCH-L1 siRNA du-
plexes were tested at ﬁnal concentrations of 25 (0.12 g), 50 (0.24 g), or 100
nmol/l (0.48 g). Cells were transfected with UCH-L1 siRNA or control siRNA
(scramble) in Opti-MEM (Invitrogen) for 6 h before switching to fresh culture
medium; cells were lysed 24, 48, or 72 h after transfection.
Immunoﬂuorescent staining. INS 832/13 cells were plated in four-well
chamber permanox slides (Nunc, Rochester, NY) at 100,000 cells per well.
After the treatment (as indicated), the immunoﬂuorescence procedure was
performed as described in 33. Cells were incubated overnight at 4°C with
anti-CHOP antibody, followed by a 1-h treatment with secondary antibody
conjugated to Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA).
Slides were viewed using a Leica DM6000 microscope (Leica Microsystems,
Bannockburn, IL) and imaged using Openlab software (Improvision, Lexing-
ton, MA). The immunoﬂuorescence of rat and human tissues was as described
(1).
Image analysis. For detailed evaluation of -cells positive for ubiquitin, 15
islets per case were selected randomly. The -cell was considered to be
positive if it had any labeling with intensity above background staining of
exocrine pancreas. For the quantiﬁcation of CHOP immunostaining, images of
six randomly chosen ﬁelds were taken at 10 magniﬁcation. The cells
containing nuclear CHOP labeling with intensity above background and the
total number of cells in each ﬁeld were counted. Results were expressed as
the percentage of CHOP-positive cells.
Statistical analysis. Results are expressed as the means  SE for n
independent experiments, as indicated in ﬁgure legends. Statistical analyses
were carried out by Student t test or ANOVA followed by Fisher post hoc test
for multiple comparisons using Statistica (Statsoft, Tulsa, OK). A P value of
0.05 was taken as evidence of statistical signiﬁcance (*P  0.05; **P  0.01;
***P  0.001).
RESULTS
Accumulation of polyubiquitinated proteins in
-cells of humans with type 2 diabetes abrogated by
insulin therapy. To test the hypothesis that the ERAD/
ubiquitin/proteasome system is dysfunctional in type 2 dia-
betes, we ﬁrst examined pancreatic tissue and isolated islets
from humans with type 2 diabetes versus BMI-matched
control subjects (supplementary Tables 1 and 2). The per-
centage of -cells immunostained for ubiquitin was un-
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2.1  1.3%, P  NS, obese nondiabetic vs. lean nondiabetic)
(Fig. 1A and B), implying that in health, the -cell ERAD/
ubiquitin/proteasome system adapts to the increased syn-
thetic burden of insulin and IAPP prompted by obesity-
mediated insulin resistance (6,7). In contrast, the percentage
of -cells with ubiquitin immunostaining was increased (ap-
proximately fourfold) in obese individuals with type 2 diabe-
tes treated with diet and/or sulfonylureas in comparison to
obese nondiabetic individuals (25  6% vs. 6.8  2%, P 
0.05) (Fig. 1A and B). Ubiquitin immunostaining in islets
was mostly cytoplasmic, although nuclear staining was
also found in some cells, consistent with previous
reports documenting the presence of components of the
ubiquitin-proteasome pathway in both cytoplasmic and
nuclear compartments (34) and implying that defective
protein degradation may also alter clearance of nuclear
proteins.
Western blot analysis of isolated islets obtained from
three individuals with type 2 diabetes and three BMI-
matched nondiabetic control subjects (supplementary
Table 1) revealed high–molecular weight smears that
correspond to polyubiquitinated proteins (Fig. 1C). A
stronger ubiquitin signal was detected in islets from indi-
viduals with type 2 diabetes (Fig. 1C), corroborating the
increased ubiquitin staining detected by immunohisto-
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diabetes.
Interestingly, we found that the percentage of -cells
positive for ubiquitin in obese individuals with type 2
diabetes treated with insulin was decreased in comparison
to individuals treated with diet only or oral sulfonylureas
(3.6  1.4% vs. 25  6%, P  0.01) (Fig. 1A and B), perhaps
through the decreased ER synthetic burden mediated by
exogenous insulin. IAPP production would be an interest-
ing parameter to follow in this study. Unfortunately, it is
not available for these groups of subjects, and relative
expression rates can only be inferred from animal studies.
Because accumulation of polyubiquinated proteins in
neurodegenerative diseases has been attributed to dys-
function of the ERAD/ubiquitin/proteasome rendered by
accumulation of amyloidogenic proteins, we next investi-
gated whether the accumulation of polyubiquitinated pro-
teins in -cells is induced by increased expression of
amyloidogenic h-IAPP.
Pancreatic -cells from HIP rats display high levels of
ubiquitinated proteins associated with decreased
UCH-L1 protein expression. We studied 4- to 6-month-
old h-IAPP transgenic rats (HIP rat) versus wild-type rats.
At this age, HIP rats have increased -cell apoptosis but do
not yet have diabetes, allowing us to avoid the confound-
ing effects of glucose toxicity (RESEARCH DESIGN AND METHODS)
(10,14). The percentage of -cells immunostained for
ubiquitin was increased in HIP rats (32  5% vs. 8  5%,
P  0.01) (Fig. 2A and B). The staining was mostly
cytoplasmic, although nuclear staining was also evident in
some cells (Fig. 2A). To draw a parallel between obese
individuals with type 2 diabetes and the rat model, we also
examined pancreatic sections from HFD-fed HIP rats (6).
Within this group of HFD-fed HIP rats, which have diabe-
tes and are insulin resistant, the percentage of -cells
stained for ubiquitin was increased in comparison to HIP
rats fed with a regular diet (50  3% vs. 32  5%, P  0.05)
(Fig. 2B). Ubiquitin immunostaining was predominantly
cytoplasmic, although nuclear staining was present in
some cells, comparable to islets in type 2 diabetes (Fig.
1A). Impaired proteasome function may cause accumula-
tion of ubiquitinated proteins (18). However, proteasome
activity was comparable in islets of HIP, HFD-fed HIP, and
wild-type rats (Fig. 2C).
UCH-L1 permits ubiquitinated proteins to access the
proteasome and when deﬁcient may lead to accumulation
of polyubiquinated proteins (27–29). Therefore, we next
investigated UCH-L1 expression in HIP rat islets. UCH-L1
protein levels were decreased by 42  9% in islets of HIP
compared with wild-type rats (P  0.01) (Fig. 3B). UCH-L1
mRNA levels were also downregulated by 28  6% in HIP
rat islets (P  0.05) (Fig. 3C). This downregulation was
supported by microarray analysis of HIP versus wild-type
rat islets (data not shown). These results suggest that
decreased UCH-L1 protein expression occurred, at least in
part, at a transcriptional level. Accumulation of ubiquiti-
nated proteins (Fig. 3A) and decreased UCH-L1 protein
expression were also related to ER stress and apoptosis in
HIP rat islets, as shown by increased CHOP expression
and increased cleaved caspase-3 respectively (Fig. 3B) (6).
Also, the frequency of -cells positive for ubiquitin was
highly correlated to -cell ER stress and -cell apoptosis
(r  0.8, P  0.001, and r  0.7, P  0.01, respectively)
(supplementary Fig. 1A and B). These data suggest that
high expression rates of h-IAPP lead to the accumulation
of ubiquitinated proteins and downregulation of UCH-L1 in
vivo.
h-IAPP but not r-IAPP expression decreases UCH-L1
protein level in -cells. To establish whether UCH-L1
downregulation is caused by h-IAPP, we studied INS 832/13
cells transduced with adenoviruses expressing h-IAPP or the
nonamyloidogenic and nontoxic rodent IAPP (r-IAPP), as
control for a comparable burden of protein expression (33).
Cells transduced with h-IAPP (400 MOI, 48 h) exhibited a
31  10% decrease in UCH-L1 protein expression in compar-
ison to r-IAPP-transduced cells (P  0.05) (Fig. 4). Therefore,
high expression rates of h-IAPP lead to UCH-L1 downregu-
lation in -cells, and this effect is due to the amyloidogenic
properties of h-IAPP rather than just protein overload.
Loss of UCH-L1 function and expression leads to
ER stress and -cell apoptosis. To evaluate whether
UCH-L1 downregulation plays a role in the progression of
h-IAPP–induced -cell apoptosis, we treated INS 832/13
cells with UCH-L1 inhibitor, LDN-57444, for 18 h at differ-
ent concentrations. Inhibition of UCH-L1 function led to
increased caspase-3 activity and cleavage at concentra-
tions above 30 mol/l (Fig. 5A and B). We next investi-
gated whether apoptosis induced by UCH-L1 inhibitor was
related to ER stress. Western blot analysis showed induc-
tion of CHOP after exposure to UCH-L1 inhibitor (Fig. 5B)
and immunostaining revealed that nuclear CHOP was
highly induced in LDN-57444–treated cells (13.4  0.4% vs.
2.5  0.8%, P  0.01) (Fig. 5C). An increased phosphory-
lation of eukaryotic initiation factor 2 (eIF2)-, a target of
Perk and ER stress marker, was also detected by Western
blot (supplementary Fig. 2A).
To further corroborate these ﬁndings, we used a siRNA
approach to speciﬁcally target UCH-L1 and decrease its
expression. Transfection of INS 832/13 cells using 25
nmol/l of siRNA resulted in 44  6% knockdown of
UCH-L1 protein content (Fig. 6A and B), reproducing the
deﬁcit observed in HIP rat islets (Fig. 3B). This decrease in
protein content was associated with a decrease in UCH-L1
activity (Fig. 6A and B), as shown by labeling studies using
Ub-VS active site probe for deubiquitinating enzymes. This
probe (with an HA tag) covalently modiﬁes active deubiq-
uitinating enzymes in the extracts. Examination of Ub-VS–
treated extracts from control or scramble-transfected cells
revealed several HA reactive bands, including a 35-kDa
band corresponding to UCH-L1 complexed with the probe
(35). This band was decreased by 	40% in UCH-L1 siRNA-
transfected cells (Fig. 6A and B), conﬁrming a decrease in
active UCH-L1. This decrease in UCH-L1 protein content
and activity led to increase of cleaved caspase-3 and of its
cleaved substrate PARP (Fig. 6A and B). Immunostaining
revealed that nuclear CHOP was highly induced in UCH-
L1–downregulated cells in comparison to scramble-trans-
fected cells (23  3% vs. 6.3  1.3%, P  0.01) (Fig. 6C). ER
stress was also conﬁrmed by the increase in eIF2-
phosphorylation upon UCH-L1 downregulation (supple-
mentary Fig. 2B). In conclusion, chemical inhibition as
well as knockdown of UCH-L1 leads to accumulation of
ubiquitinated proteins (supplementary Fig. 3), ER stress,
and apoptosis in -cells.
To determine whether a decrease in UCH-L1 exacer-
bates h-IAPP–induced apoptosis, we transfected INS
832/13 cells with UCH-L1 siRNA or scramble (25 nmol/l,
36 h) and transduced these cells with h-IAPP or r-IAPP
adenoviruses at 300 MOI for 30 h. Under these conditions,
neither UCH-L1 siRNA nor h-IAPP alone induced cell
death as illustrated by cleaved caspase-3 and cleaved
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activity (data not shown). UCH-L1 knockdown increased
the cleavage of caspase-3 and PARP in both r-IAPP– and
h-IAPP–transduced cells in comparison to scramble-trans-
fected cells. However, when UCH-L1 was knocked down
in the presence of h-IAPP, cell death was induced to a
greater extent in comparison to r-IAPP–transduced cells
(supplementary Fig. 4A and B, lane 8 vs. lane 9, P 
0.001). These results demonstrate the critical role of
UCH-L1 for -cell survival under conditions of a high
protein synthetic burden.
Increased expression of h-IAPP in isolated human
islets leads to accumulation of polyubiquitinated
proteins associated with decreased UCH-L1 protein
level. To establish whether h-IAPP affects the ubiquitin/
proteasome pathway in human -cells, we transduced
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5). The activity was normalized to the total protein content. The proteasome inhibitor, lactacystin (Lacta; 25 mol/l) was used as negative
control. Data are expressed as means  SE. *P < 0.05; ***P < 0.001, signiﬁcant differences vs. wild type. ns, nonsigniﬁcant. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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IAPP or r-IAPP (400 MOI, 72 h). The accumulation of
polyubiquitinated proteins was signiﬁcantly increased
(1.8  0.1-fold, P  0.01) in human islets transduced with
h-IAPP, as shown by Western blot analysis (Fig. 7A). To
address the mechanism by which h-IAPP leads to the
accumulation of ubiquitinated proteins in human islets, we
examined its actions on proteasome activity as well as on
UCH-L1 expression. There was no change in proteasome
activity in human islets transduced with h-IAPP in com-
parison to islets transduced with r-IAPP (Fig. 7B). How-
ever, overexpression of h-IAPP led to a 40  5% decrease
in UCH-L1 protein expression (P  0.01) (Fig. 7C), sup-
porting the data obtained in both HIP rat islets (Fig. 3B)
and INS 832/13 cells (Fig. 4) and suggesting that a speciﬁc
property of h-IAPP is responsible for accumulation of
polyubiquitinated proteins and UCH-L1 downregulation in
human -cells.
UCH-L1 protein level is decreased in -cells of indi-
viduals with obesity and type 2 diabetes. To investi-
gate whether UCH-L1 deﬁciency occurs in individuals with
type 2 diabetes, we examined protein levels in isolated
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and three obese individuals with type 2 diabetes (OD
group) (supplementary Table 1). Western blot analysis of
these samples showed decreased UCH-L1 protein levels
normalized to -tubulin in individuals with type 2 diabetes
versus BMI-matched nondiabetic control subjects. Insulin
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with type 2 diabetes, and this may either reﬂect diminished
number of -cells per islet and/or depleted insulin stores
per -cell. UCH-L1 protein levels in type 2 diabetes remain
decreased even when normalized to insulin (46  14%, P 
0.05) (Fig. 8A), presumably a conservative estimate of the
extent of the deﬁcit.
In addition, analysis of pancreata stained by immunoﬂu-
orescence for UCH-L1 revealed diminished staining of
-cells in individuals with type 2 diabetes in comparison to
nondiabetic individuals (Fig. 8B) (supplementary Table 4).
These observations support the data obtained by Western
blot, indicating that UCH-L1 protein levels are decreased
in -cells of individuals with type 2 diabetes. Interestingly,
UCH-L1 protein expression was inversely related to the
accumulation of polyubiquitinated proteins in -cells of
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these data reveal that decreased UCH-L1 availability and
accumulation of poyubiquitinated proteins are character-
istics of -cells in type 2 diabetes.
DISCUSSION
We report that the ERAD/ubiquitin/proteasome system is
dysfunctional in -cells of individuals with type 2 diabetes
as demonstrated by the accumulation of polyubiquinated
proteins. This further supports that islet dysfunction in
type 2 diabetes and neuronal dysfunction in neurodegen-
erative diseases share common mechanisms. In most
neurodegenerative diseases, dysfunction of the ERAD/
ubiquitin/proteasome system is a consequence of amyloi-
dogenic protein aggregates that, by disrupting this system,
further compound their adverse actions (23). An intriguing
ﬁnding in our studies supports that model. Accumulation
of polyubiquinated proteins was decreased in -cells of
individuals with type 2 diabetes treated with insulin ther-
apy in comparison to those treated by sulfonylureas and
diet therapy, even though the blood glucose control was
comparable. Insulin therapy might thus be expected to
protect -cells against dysfunction of the ERAD/ubiquitin/
proteasome system by reducing the synthetic burden for
both insulin and IAPP in type 2 diabetes.
Having established that the ERAD/ubiquitin/proteasome
system is compromised in -cells of humans with type 2
diabetes, we sought to examine if this can be reproduced
by increased h-IAPP expression. Moreover, we sought to
establish if the underlying defect is at the proteasome level
or because of decreased UCH-L1 availability. We report
that UCH-L1 protein levels are decreased in -cells of
humans with type 2 diabetes, and this is accompanied by
accumulation of ubiquitin conjugates. Hyperglycemia, per
se, can lead to decreased UCH-L1 expression (25), but our
data suggest that h-IAPP misfolding has an independent
action on UCH-L1 expression and function. We examined
islets from HIP rats at 4 to 6 months of age before this
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tion (10,14). In those studies, as well as those with isolated
human islets and INS 832/13 cells expressing h-IAPP
versus r-IAPP, the actions of h-IAPP to compromise
UCH-L1 availability were documented independently of
glucose toxicity. Moreover, dysfunction of the ERAD/
ubiquitin/proteasome system with decreased UCH-L1
availability in neurodegenerative diseases characterized
by misfolded amyloidogenic proteins occurs in the ab-
sence of diabetes. Therefore, we speculate that the defect
in protein degradation apparent in -cells in type 2 diabe-
tes can, at least in part, be attributed to misfolded h-IAPP
leading to UCH-L1 deﬁciency, which in turn likely further
compromises -cell viability by exacerbating ER stress.
These ﬁndings raise the question, how does amyloido-
genic h-IAPP lead to decreased UCH-L1 availability?
UCH-L1 mRNA and protein expression were decreased in
HIP rat islets, but the mechanisms responsible for this
downregulation remain to be elucidated. UCH-L1 tran-
scriptional repression was shown to be mediated through
CpG hypermethylation of its promoter in renal cells (36).
Interestingly, ER stress induces transcriptional repression
through promoter hypermethylation (37). Therefore, h-
IAPP–mediated ER stress could lead to hypermethylation
of the UCH-L1 gene promoter, leading to decreased mRNA
and protein levels. Post-transcriptional and post-transla-
tional modiﬁcations of UCH-L1 might also account for
decreased UCH-L1 availability. In neurons from individu-
als with Alzheimer’s or Parkinson’s disease, UCH-L1 pro-
tein expression is decreased and is also a major target of
oxidative damage (24). UCH-L1 is thus extensively modi-
ﬁed by carbonyl formation, leading to alteration of its
activity (38). -Cells are highly vulnerable to oxidative
stress that is a characteristic in type 2 diabetes (39).
Because h-IAPP oligomers disrupt -cell mitochondrial
integrity (15), it is likely that h-IAPP contributes to -cell
oxidative stress (40) that is compounded by subsequent
hyperglycemia. We conclude that h-IAPP oligomers may
induce UCH-L1 deﬁciency by decreasing UCH-L1 gene
expression and/or by the way of post-translational modi-
ﬁcations mediated through oxidative damage.
Although we reproducibly demonstrated that h-IAPP
induced UCH-L1 downregulation in different models, en-
dogenous h-IAPP expression did not decrease proteasome
activity. Proteasome activity was decreased in human
islets incubated with applied exogenous h-IAPP (41). This
discrepancy can be explained by the differences between
exogenously applied h-IAPP (41) and endogenously ex-
pressed h-IAPP. Application of toxic protein oligomers
extracellularly bypasses the ERAD/ubiquitin/proteasome
system for removal of toxic oligomers as they are formed.
The overwhelming actions of this approach induce apo-
ptosis in most cells within 24 h (9). However, data are
accumulating to suggest that toxic h-IAPP oligomers form
intracellularly in some -cells in type 2 diabetes (15) and
have a more subtle effect on -cell viability and function as
described in animal models that develop diabetes through
transgenic expression of h-IAPP (42).
The lack of an adverse effect of endogenously expressed
h-IAPP on proteasome catalytic activity suggests that h-IAPP
compromises the ubiquitin/proteasome system upstream of
the proteasome. Because ubiquitinated proteins accumulate
with increased h-IAPP, we considered that the ubiquitination
process itself is unlikely to be perturbated. A more plausible
explanation for accumulation of ubiquinated proteins with
increased expression of h-IAPP is compromised delivery of
ubiquitinated proteins to the proteasome. Degradation of
proteins targeted for proteasomal degradation may be al-
tered by abnormal modiﬁcations of substrates, per se, im-
pairing their binding and/or recognition by the functional 20S
proteasome. Thus, accumulation of ubiquitinated proteins
may be a consequence of inhibition of deubiquitinating
activity rather than direct effect on the proteasome (43). We
hypothesized that in -cells expressing h-IAPP, deﬁcient
UCH-L1 availability might lead to impaired polyubiquitin
removal from proteins targeted for degradation before entry
into the 20S proteasome, leading to the obstruction of the 20S
pore by a forked substrate. Consistent with this hypothesis,
we and others have demonstrated that inhibition of UCH-L1
led to accumulation of ubiquitinated proteins (27–29).
Modiﬁcation of a protein with ubiquitin chains is the
hallmark of protein degradation by the proteasome. How-
ever, recent data imply a role for ubiquitin in lysosome-
dependent degradation, known as autophagy (44). In
rodent -cells, defects in autophagy are associated with
accumulation of polyubiquitinated proteins (45–47). Also,
-cells in type 2 diabetes show evidence of altered auto-
phagy (48). Interestingly, the intracellular storage of ubi-
quitinated aggregates in patients with lysosomal storage
disorders is associated with deﬁciency of UCH-L1 (28).
Recently, the p62/autophagy/lysosomal degradation sys-
tem, an alternative mechanism to clear ubiquinated pro-
teins, was shown to be compromised by high expression
of h-IAPP (32). Given the approximately 40% decreased
availability of UCH-L1 protein (and possibly further de-
creased function through post-translational modiﬁcations,
vida supra) and impaired autophagy in -cells in type 2
diabetes (48), both major pathways for removal of mis-
folded proteins are dysfunctional. Moreover, the rate of
formation of misfolded proteins per -cell requiring deg-
radation is likely increased given the conditions of insulin
resistance and decreased -cell number as well as com-
promised ER function arising from ER stress and dis-
rupted ER Ca
2
 homeostasis induced by membrane
permeant oligomers (15,33) and glucolipotoxicity.
Arguments in favor of a relatively early role of impaired
-cell protein homeostasis include the early presence of
impaired -cell function that precedes type 2 diabetes
(49), reproduced in the HIP rat (14). However, increased
expression of h-IAPP upon obesity is insufﬁcient alone to
explain why 	20% of individuals with morbid obesity
develop type 2 diabetes, whereas 80% do not. The contrib-
utor factors that may explain this include variance be-
tween individuals in the efﬁciency of protein chaperoning
through the secretory pathway and variance in the -cell
mass accomplished during postnatal expansion. The latter
results in a wide range of -cell mass in young adults (50)
and therefore presumably -cell synthetic burden in indi-
viduals that subsequently become obese.
Because elimination of misfolded proteins is important
for cell viability, we investigated the effects of UCH-L1
availability on -cell viability. High expression of h-IAPP
induces -cell apoptosis through the mechanism of ER
stress (1,16), but the precise molecular events triggering
ER stress are unknown. Here, we show that increased
expression of h-IAPP (but not r-IAPP) decreased UCH-L1
levels and that loss of UCH-L1 expression and activity
induced ER stress and apoptosis in -cells. Therefore,
increased h-IAPP expression induces ER stress and -cell
apoptosis that is mediated, at least in part, by abnormal
function of UCH-L1. In addition, the accumulation of
ubiquitinated proteins might also exacerbate ER stress
UBIQUITIN-DEPENDENT DEGRADATION AND HUMAN-IAPP
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-cell function to -cell apoptosis is driven by this unsus-
tainable cycle once UCH-L1 function and the back up
pathway of autophagy are attenuated.
In summary, we report that -cells in type 2 diabetes
share the characteristics of affected neurons in Alzhei-
mer’s and Parkinson’s diseases with attenuated UCH-L1
protein levels and accumulation of ubiquitin conjugates.
Increased expression of h-IAPP in -cells, as occurs in
insulin resistant states such as obesity, can lead to the
formation of h-IAPP toxic oligomers and accumulation of
polyubiquitinated proteins associated with decreased
UCH-L1 availability. Downregulation of UCH-L1 expres-
sion and activity in -cells induces ER stress and apopto-
sis. We conclude that a defective protein degradation
system in -cells in type 2 diabetes can, at least in part, be
attributed to misfolded h-IAPP leading to UCH-L1 deﬁ-
ciency, which in turn further compromises -cell viability.
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